Back to search

National and Kapodistrian University of Athens

Συστηματική φλεγμονώδης αντίδραση σε πειραματικό μοντέλο πολυτραυματία: η θέση της θαλιδομίδης

Abstract

dc:description

Introduction. Severe trauma is one of the main causes of the systemic inflammatory response syndrome (SIRS), potentially leading to clinical deterioration and patient death. The role of the immune system is central in the pathogenesis of SIRS. A variety of pro-inflammatory cytokines are secreted by immune cells in response to trauma, and their dysregulation may lead to SIRS and multiple organ dysfunction. Tumor necrosis factor-alpha (TNFα) is a central mediator of the immune response after trauma. It appears early in serum after the traumatic event, stimulates the production of other pro-inflammatory cytokines, primes loss of integrity of vascular endothelium and drives apoptosis of lymphocytes. Therefore TNFα is considered a major target for therapies aiming to modulate the host’s immune response. Developed immunomodulatory strategies so far comprise monoclonal antibodies targeting TNFα and soluble TNF receptors. These agents failed to show any survival benefit in clinical studies in patients with severe sepsis, probably indicating that strategies aiming to modulate excess production of TNFα require another approach. Thalidomide (a-N-phthalimidoglutarimide) was initially used as a sedative and antiemetic during pregnancy but it was withdrawn from the market due to its teratogenic effects. It is an immunomodulatory compound that selectively inhibits TNFα synthesis by reducing the half-life of mRNA in human monocytes. Thalidomide is160currently used for its anti-angiogenic and anti-TNF properties in the treatment of a variety of diseases like erythema nodosum leprosum, Crohn’s disease, multiple myeloma and HIV-related aphthous ulcers. In a previous study, thalidomide was administered orally to rats as pre-treatment for experimental sepsis. It prolonged survival and reduced circulating levels of TNFα. However, oral administration of the drug in shocked animals is not feasible. Therefore, an intravenous thalidomide formulation was prepared and administered for the management of lethal injury in an experimental study in rabbits.Materials and methods. Thirty white New Zealand male rabbits with mean (±SD) weight 3.37 ±0.35 kg were used in the study. Thalidomide is sparingly soluble in water and undergoes rapid spontaneous hydrolysis in the physiologic pH range. Therefore thalidomide solutions of 0.2 mg/mL, 0.5 mg/mL and 1 mg/mL in 5% Dextrose Water (DW) were produced following thalidomide complexation with (2-hydroxy-propyl)-β-cyclodextrin. Pharmacokinetics of the prepared solutions was established by intravenously administering them to six animals. Thalidomide concentrations in prepared solutions and animal sera were determined by a HPLC method. All prepared solutions were stable. Animals receiving the 1.0 mg/mL solution had mean (±SD) thalidomide serum concentrations of 7.30±1.50 μg/mL at the end of infusion and 5.82±1.45 μg/mL, 60 min post-infusion. Based on these results the 1 mg/mL solution was deemed appropriate for administration in the rest of the study. Following an open fracture of the right femur, 24 rabbits were assigned to groups A (controls) and B (thalidomide). Group A (n=14) were administered 30 ml of 5% DW within 15161minutes, starting 30 minutes after the femoral fracture. Group B (n=10) were administered 30 ml of the 1mg/mL prepared thalidomide solution in 5% DW within 15 minutes, starting 30 minutes after the femoral fracture. Hemodynamic monitoring was performed for 4 hours, survival was recorded and bacterial growth in organs was measured. Blood was sampled at time 0 and at 2, 4, 24 and 48h for TNFα measurement, isolation of peripheral blood mononuclear cells (PBMCs) and culture. TNFα was measured by a bioassay on the L929 fibrosarcoma cell line and apoptosis of PBMCs was measured by flow cytometry after staining with ANNEXIN-V and propidium iodide (PI). Cells staining positive for ANNEXIN-V and negative for PI were considered apoptotic. An ex-vivo experiment was performed incubating PBMCs from healthy animals and humans with sera from groups A and B sampled at 2h and 24h post injury and measuring induction of apoptosis as described above.Results. Survival of group B was considerably prolonged compared with group A (log rank = 5.543, p = 0.019). Clarification of the possible mechanism of action of thalidomide, was focused on an effect on i) animal hemodynamics; ii) tissue bacterial growth; iii) circulating TNFα; and iv) apoptosis of circulating mononuclear cells. No differences were found between groups A and B regarding systolic, diastolic and mean arterial pressures and heart rate showing that thalidomide was not acting on animal hemodynamics. In a similar fashion, all blood cultures in both groups were negative for bacterial growth and quantitative tissue cultures of spleen, liver and lung did not differ between group. Bacterial isolates were species of enterobacteriaceae. Circulating concentrations162of TNFα at baseline and at 2h and 4h after injury did not differ between the two groups. As a consequence, a hypothesis was generated that thalidomide exerted its effect via an immunomodulatory action that did not involve TNFα inhibition. To test this, the apoptotic rate of PBMCs between the two groups was compared. It became obvious that PBMC apoptosis was increased in the control group compared to the thalidomide group and this was significant at 2h and 24h after injury. The observation of decreased PBMC apoptosis among thalidomide-treated rabbits, elaborated the hypothesis that a circulating factor may exist, other than TNFα, that is responsible for this apoptosis modulation. To this end, serum from control and treated animals was incubated with PBMCs of healthy rabbits. Since differences in apoptosis of PBMCs were identified at 2h and 24h, it was considered that serum sampled at these time intervals should be applied for testing. Serum of treated animals sampled at 24h, i.e. long after the peak levels of thalidomide as defined by the preliminary pharmacokinetic analysis, induced apoptosis of lymphocytes. The possibility of an interspecies activity of the serum factor was examined. Human lymphocytes incubated with sera from both groups collected at 24h post injury did not show any difference in their early apoptotic rates.Conclusion. Intravenous thalidomide administration in an experimental model of lethal musculoskeletal injury in rabbits:1) Prolonged animal survival.2) Its mechanism of action did not involve TNFα suppression.1633) Exerted an immunomodulatory effect preventing apoptosis of PBMCs by inhibition of an unidentified serum factor.In view of these promising results, further research is needed to clarify the immunomodulatory mechanism of action of thalidomide and its potential use for the management of severe trauma.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Panousis, Konstantinos
  • Πανούσης, Κωνσταντίνος

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/29730

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Panousis, Konstantinos; Πανούσης, Κωνσταντίνος. Συστηματική φλεγμονώδης αντίδραση σε πειραματικό μοντέλο πολυτραυματία: η θέση της θαλιδομίδης. National and Kapodistrian University of Athens, 2012. http://hdl.handle.net/10442/hedi/29730